Ascendiant Capital Markets Forecasts PSTV Q2 Earnings

Plus Therapeutics, Inc. (NASDAQ:PSTV) – Research analysts at Ascendiant Capital Markets cut their Q2 2026 earnings estimates for shares of Plus Therapeutics in a note issued to investors on Saturday, June 6th. Ascendiant Capital Markets analyst E. Woo now anticipates that the company will post earnings of ($0.92) per share for the quarter, down from their previous estimate of ($0.89). Ascendiant Capital Markets currently has a “Buy” rating and a $57.00 target price on the stock. The consensus estimate for Plus Therapeutics’ current full-year earnings is ($3.66) per share. Ascendiant Capital Markets also issued estimates for Plus Therapeutics’ Q3 2026 earnings at ($0.92) EPS, Q4 2026 earnings at ($0.93) EPS, FY2026 earnings at ($3.77) EPS, Q1 2027 earnings at ($0.77) EPS, Q2 2027 earnings at ($0.77) EPS, Q3 2027 earnings at ($0.63) EPS, Q4 2027 earnings at ($0.63) EPS and FY2027 earnings at ($2.81) EPS.

PSTV has been the topic of a number of other reports. Wall Street Zen raised shares of Plus Therapeutics to a “sell” rating in a research report on Saturday, April 4th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Plus Therapeutics in a research report on Tuesday, April 21st. Finally, D. Boral Capital reaffirmed a “hold” rating on shares of Plus Therapeutics in a research report on Tuesday, March 31st. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $56.40.

Plus Therapeutics Trading Down 2.0%

Plus Therapeutics stock opened at $5.39 on Thursday. The stock has a market cap of $37.10 million, a P/E ratio of -2.34 and a beta of 1.38. The company has a fifty day simple moving average of $5.65 and a 200-day simple moving average of $8.46. Plus Therapeutics has a 12-month low of $2.90 and a 12-month high of $23.42.

Plus Therapeutics (NASDAQ:PSTV) last released its quarterly earnings data on Friday, May 15th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.20). The firm had revenue of $1.03 million for the quarter, compared to analysts’ expectations of $0.97 million. Plus Therapeutics had a negative return on equity of 198.48% and a negative net margin of 230.24%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Virtu Financial LLC purchased a new position in Plus Therapeutics during the 4th quarter worth $254,000. XTX Topco Ltd purchased a new position in Plus Therapeutics during the 4th quarter worth $127,000. State Street Corp grew its position in Plus Therapeutics by 37.1% during the 4th quarter. State Street Corp now owns 468,893 shares of the company’s stock worth $240,000 after purchasing an additional 127,000 shares during the last quarter. L1 Global Manager Pty Ltd purchased a new position in Plus Therapeutics during the 4th quarter worth $1,167,000. Finally, Jane Street Group LLC purchased a new position in Plus Therapeutics during the 4th quarter worth $525,000. 3.28% of the stock is owned by hedge funds and other institutional investors.

Plus Therapeutics Company Profile

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.